FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 68948

News■ Unclear/unknown

Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)

EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 11:08 UTC
LAST UPDATE2026-10-07 11:08 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Phase 2 enrollment completion for an IPF antibody is a clinical milestone for a private biotech.

Clinical progress in private biotech, no listed angle
CATALYST TO WATCH

Phase 2 topline data release

MAIN RISK

Efficacy or safety failure at readout

FULL DISPATCH

First-in-class antibody MTX-463 targets WISP-1, a secreted matricellular protein implicated in fibrosis progression Global study rapidly enrolled 168 patients across 70+ sites spanning North and South America, Europe and Australia BOSTON, Oct. 7, 2026 /PRNewswire/ -- Mediar Therapeutics,...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

CONTEXTEurope
AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-10-07 11:08 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.